Tumor Angiogenesis and Anti-VEGF Therapy: How Cancers Build Their Own Blood Supply

What it is and why it matters clinically

Angiogenesis is the sprouting of new capillaries from pre-existing vessels. In healthy adults it is largely quiescent—confined to wound healing, the menstrual cycle, and placental development. Tumors hijack this dormant program. Because oxygen diffuses only ~100–200 µm through tissue, a tumor can survive as an avascular nodule of roughly 1–2 mm, but no larger, until it flips the angiogenic switch: a shift in the balance between pro-angiogenic factors (VEGF-A, FGF, PDGF, angiopoietins) and endogenous inhibitors (thrombospondin-1, endostatin, angiostatin).

This matters clinically for three reasons. First, angiogenesis is a validated hallmark of cancer and a druggable target. Second, tumor vessels are the route by which cancer cells intravasate and metastasize, so vascular biology links directly to spread. Third, the vasculature that tumors build is structurally abnormal—leaky, tortuous, and poorly perfused—which paradoxically impairs delivery of chemotherapy and creates a hypoxic, immunosuppressive microenvironment. Understanding the switch is what made anti-VEGF therapy possible.

The mechanism, step by step

The cascade begins with hypoxia at the growing tumor core:

• Oxygen sensing: Under normoxia, prolyl hydroxylases (PHDs) tag HIF-1α for VHL-mediated ubiquitination and degradation. In hypoxia—or when the VHL tumor suppressor is lost (classic in clear-cell renal cell carcinoma)—HIF-1α is stabilized and accumulates.
• Transcription: HIF-1α dimerizes with HIF-1β and transactivates VEGF-A, plus erythropoietin, GLUT1, and glycolytic genes.
• Receptor signaling: Secreted VEGF-A binds VEGFR-2 (KDR/Flk-1) on endothelial cells, triggering autophosphorylation and downstream PLCγ→PKC→RAS→MAPK (proliferation) and PI3K→AKT (survival, plus eNOS-mediated permeability).
• Sprouting: A leading tip cell—selected by Notch/DLL4 lateral inhibition—extends filopodia toward the VEGF gradient, while trailing stalk cells proliferate to elongate the sprout. Matrix metalloproteinases degrade basement membrane; pericytes are recruited by PDGF-B.

The result is a disorganized, hyperpermeable vascular network rather than an orderly capillary bed.

Clinical presentation and the vascular phenotype

Tumor angiogenesis has no single bedside sign in the patient—it is a microscopic process—but it manifests in characteristic clinical and pathologic phenotypes:

• Hypervascular tumors on imaging: Hepatocellular carcinoma, renal cell carcinoma, and neuroendocrine tumors show avid arterial-phase enhancement with washout on contrast CT/MRI—a direct readout of dense neovasculature.
• Bleeding and effusions: Leaky, fragile tumor vessels cause hemoptysis (lung), hematuria (renal/bladder), GI bleeding, and malignant ascites/pleural effusions driven by VEGF-mediated permeability.
• Microvessel density (MVD): On histology, high MVD—quantified by counting CD31- or CD34-stained vessels in a tumor "hot spot" (the Weidner method)—correlates with poor prognosis in breast, prostate, and other cancers.

Because the vasculature is abnormal, tumors are often hypoxic and acidic despite being highly vascular—a paradox that fuels treatment resistance and selects for more aggressive clones. The vessels lack a normal pericyte coat and continuous basement membrane, so they are prone to leak and rupture.

Diagnosis and how angiogenesis is measured

Angiogenesis is assessed indirectly through pathology, imaging, and molecular markers rather than a single diagnostic test:

• Immunohistochemistry: Endothelial markers CD31 (PECAM-1) and CD34 highlight microvessels; MVD counting in the most vascular field is the classic quantitative surrogate.
• Functional imaging: DCE-MRI (dynamic contrast-enhanced MRI) yields the transfer constant Ktrans, a marker of vascular permeability and flow that falls after effective anti-angiogenic therapy. CT/MR perfusion measures blood volume and flow.
• Molecular/serum markers: Circulating VEGF-A, soluble VEGFR-2, and placental growth factor (PlGF) shift on treatment, though none is a validated companion diagnostic. High HIF-1α or VEGF expression carries prognostic weight.

Importantly, there is no approved predictive biomarker that reliably selects patients for anti-VEGF therapy—unlike EGFR or HER2 for targeted agents. Clinically, treatment-emergent hypertension has been observed to associate with better outcomes in several trials, acting as a crude pharmacodynamic marker of on-target VEGF blockade.

Management: how anti-VEGF drugs work, and their toxicities

Anti-angiogenic drugs interrupt the VEGF axis at three levels, and their benefit stems partly from vascular normalization—pruning immature vessels and transiently improving perfusion so chemotherapy and oxygen reach the tumor:

• Ligand sequestration: Bevacizumab (humanized anti-VEGF-A mAb) and aflibercept (a VEGF-trap fusing VEGFR-1 domain 2 and VEGFR-2 domain 3 to an IgG1 Fc) bind circulating VEGF before it reaches the receptor.
• Receptor blockade: Ramucirumab binds VEGFR-2 extracellularly, preventing ligand engagement.
• Intracellular kinase inhibition: Oral TKIs (sunitinib, sorafenib, pazopanib, lenvatinib, axitinib) block VEGFR tyrosine-kinase domains, usually alongside PDGFR, KIT, and RET.

Because VEGF also maintains normal endothelium and glomeruli, the class shares predictable, mechanism-based toxicities. Bevacizumab carries a boxed warning for GI perforation, serious hemorrhage, and impaired wound healing (hold ~28 days before/after surgery). Class effects include hypertension (30–40% any grade), proteinuria (20–60%, occasionally nephrotic-range with thrombotic microangiopathy), arterial and venous thromboembolism, and posterior reversible encephalopathy syndrome (PRES).

Distinctions, mimics, and clinical pitfalls

Several nuances separate anti-angiogenic therapy from other targeted drugs and trip up the unwary:

• Not the same as vasculogenesis: Angiogenesis sprouts vessels from existing endothelium; vasculogenesis is de novo vessel formation from bone-marrow endothelial progenitors. Tumors also use vessel co-option and vasculogenic mimicry—tumor cells lining channels—both of which are VEGF-independent and drive resistance.
• Rebound and resistance: Withdrawing anti-VEGF therapy can trigger rapid revascularization; tumors escape by upregulating FGF, PlGF, and angiopoietin-2, which is why broad multikinase TKIs sometimes outlast selective VEGF blockade.
• Distinguish drug toxicity from progression: New-onset hypertension is on-target, not tumor spread; PRES on MRI can mimic metastases; proteinuria requires urine protein-to-creatinine monitoring, and grade-3 proteinuria or nephrotic syndrome mandates holding therapy.
• Perioperative pitfall: The long half-life of bevacizumab (~20 days) means impaired wound healing and dehiscence risk persist for weeks—elective surgery must be timed around dosing.

The recurring theme: blocking VEGF is powerful but rarely curative alone, because tumors have redundant routes to a blood supply.

Major anti-angiogenic drug classes targeting the VEGF axis

Drug (class)	Molecular target	Representative indications	Distinguishing feature
Bevacizumab (humanized mAb)	VEGF-A ligand (sequesters it)	Metastatic colorectal, non-squamous NSCLC, glioblastoma, ovarian, cervical, RCC, HCC	First FDA-approved (2004); binds ligand, not receptor
Ramucirumab (human mAb)	VEGFR-2 (KDR) extracellular domain	Gastric/GEJ adenocarcinoma, NSCLC, HCC, colorectal	Blocks the receptor selectively, sparing VEGFR-1
Aflibercept / ziv-aflibercept (fusion protein)	VEGF-A, VEGF-B, PlGF (decoy 'VEGF trap')	Metastatic colorectal (with FOLFIRI)	Soluble receptor traps multiple ligands with high affinity
Sunitinib, sorafenib, pazopanib, lenvatinib, axitinib (oral TKIs)	Intracellular VEGFR-1/2/3 ± PDGFR, KIT, RET, RAF	RCC, HCC, GIST, thyroid, pancreatic NET	Multikinase; hit tumor and stroma; oral dosing